CWF19-like cell cycle control factor 2 (CWF19L2)

CWF19-like cell cycle control factor 2 (CWF19L2) is an evolutionarily conserved nuclear splicing factor predicted to be involved in mRNA splicing via the spliceosome, specifically participating in the assembly and stability of the post-mRNA release spliceosomal complex[1][2][3][8]. It is highly expressed in the nucleus of germ cells, especially throughout male germ cell development, and is essential for spermatogenesis and male fertility, where it orchestrates a network of splicing factors ensuring accurate pre-mRNA splicing[2]. Genetic deletion in mice causes severe spermatogenic defects and infertility due to defective alternative splicing of genes critical to spermatogenesis and RNA processing. Human mutations have been linked to Bardet–Biedl syndrome IV, a multisystem disorder. CWF19L2 physically interacts with multiple spliceosome components (e.g., PRPF8, PRPF43, hnRNP M) and influences key nuclear splicing processes[2][3]. While not currently a clinically actionable drug target, there is some evidence for possible interaction with cancer-associated pathways and as a putative molecular target in investigational settings[2].

Other names

CWF19-like protein 2FLJ32343CWF19 like 2, cell cycle controlCWF19L2

Not formally established; ursolic acid may target CWF19L2 in cancer therapeutics, but mechanisms remain speculative